Aldosterone may contribute to cardiovascular morbidity and mortality among patients receiving maintenance dialysis, but whether mineralocorticoid receptor antagonists improve outcomes in this population is uncertain. With the ACHIEVE trial…
ACHIEVE Fails to Show Spironolactone’s Benefits But Succeeds in Trial Implementation
